ClinicalTrials.gg
Enrolling by invitationNCT07253155Updated Nov 28, 2025

Probiotics Use and Preventing Gastrointestinal Symptoms in People Living With Overweight and Obesity.

An interventional study of Probiotic Arm and Placebo Arm in Gut Inflammation and Overweight and Obese Volunteers, sponsored by University of Ulster. Enrolling by invitation at 1 site in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-28.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's title name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Ulster · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 33 studies testing probiotic in Obesity — 9 open to participants now, 12 under way, none of them phase 3. Probiotic · Obesity.

Planned enrollment
10th of 33
100 · median 76
Started
2025
with 9 others
No phase
28 of 33
7 open now
Primary completion
2028-09
later than 11 of 11 live
Registered
29th of 33
by date

Among the 33 studies testing probiotic in Obesity, this one is the 10th largest by planned enrollment, is one of 10 that started in 2025, is one of 28 with no phase, reaches primary completion later than 11 of the 11 other live ones, and was the 29th registered.

Obesity

11,556 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

9 of the 33 studies testing probiotic in Obesity are open now, in 6 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About probiotic

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies testing probiotic in Obesity, or all of them as a file.
02

Study summary

Inflammatory bowel disease (IBD) affects over 6.8 million people worldwide, with current treatments often causing side effects and poor patient compliance. Dysbiosis of gut microbiota is a key factor, and while probiotics are considered safe and beneficial, conventional strains fail to function effectively during active inflammation due to high iron levels in the gut. Streptococcus thermophilus (FX856), unlike traditional probiotics, can thrive in this iron-rich environment, promoting mucosal healing. A 2-way crossover intervention study will be conducted with FX856 supplementation in overweight and obese individuals who often exhibit mild gut inflammation by measuring faecal calprotectin and systemic inflammatory markers.

Read the detailed description

There is a lack of satisfactory treatments for inflammatory bowel disease (IBD), an excruciatingly debilitating condition which affects 1 in 123 people in the UK (>0.5million). Current treatments have significant negative side effects, affecting quality of life of patients and reducing compliance, leading to exacerbation of symptoms. Dysbiosis in the composition of gut microbiota is one of the leading causes of chronic inflammatory diseases such as inflammatory bowel disease (IBD). Supplementation with dietary components is a promising approach for the treatment of inflammatory bowel disease (IBD) and the use of probiotics for IBD treatment has shown promising effects on consumers' quality of life, they are popular due to their perception as safe, natural treatments but currently marketed products cannot function during active disease. Streptococcus thermophilus (FX856) is an OTC supplement already available in the UK that has a unique ability to survive and thrive during active inflammation, allowing it to promote mucosal healing in the inflamed gut, an area where conventional probiotics have failed. During active inflammation or stress, gut iron levels increase. This iron-rich environment compromises the suitability of conventional probiotic bacteria that have been, and are still, commonly trailed for the relief of symptoms in patients suffering from gut inflammation. Whilst most constituents of the gut microbiome are able to increase growth rate in response to iron, species traditionally employed as probiotics, such as lactobacilli and bifidobacteria, are unable to use iron as a growth factor; they are outcompeted under high iron conditions and cannot have a beneficial effect. Unlike most bacterial strains used as probiotics, FX856 can maintain growth within an iron-rich environment, as observed in the inflamed intestine. Faecal calprotectin is considered a suitable non-invasive surrogate marker of intestinal inflammation in inflammatory bowel disease and is reported to be increased in obese individuals. Consequently, this study will determine how the probiotic FX856 interacts with the gut and immune system to reduce inflammation. A 2-way crossover intervention study will be conducted with FX856 (4 weeks) in an overweight and obese population, as such individuals are likely to have chronic mild gut inflammation and examine markers of faecal calprotectin and circulating inflammatory markers.

03

Conditions studied

  • Gut Inflammation
  • Overweight and Obese Volunteers

Browse trials for

Keywords

  • Obesity
  • gut inflammation
  • gastrointestinal symptoms
  • microbiota
  • metabolome
  • overweight
04

In context

Obesity Reclassified

11,556 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

This study's planned enrollment of 100 is above the median of 67 across 9,043 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

University of Ulster is the lead sponsor of 96 studies on the registry; 15 are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Either a 25+ kg/m2 and be aged 40+ years or have a BMI 30+ kg/m2 and aged 18+ years
  • Males and females (not currently pregnant/lactating)
  • Omnivorous diet (consuming plant \& animal based foods)
  • Not taking any medication affecting the gastro-intestinal tract
  • No chronic gastro-intestinal illness
  • Not using fibre supplements or any probiotic or prebiotic products, e.g., Fybogel, Actimel, kefir or kimchee for at least 6 weeks prior to study
  • Not consuming 7+ units of alcohol per day (e.g. 3 medium glasses of wine \~12%)

Exclusion criteria

Exclusion Criteria:

  • Not aged 40+ years (if have a 25-29.9 kg/m2)
  • BMI\<30 kg/m2 (if aged 18-39 years)
  • Pregnant/lactating female
  • Vegan/vegetarian/high protein diet
  • Chronic gastro-intestinal illness
  • Taking medication affecting the gastro-intestinal tract
  • Taking fibre supplements or any probiotic or prebiotic products
  • Consuming 7+ units of alcohol per day (e.g. 3 medium glasses of wine \~12%)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Probiotic Arm

    Probiotic supplement arm, 2 capsules consumed/day for a period of 28 days.

    Dietary Supplement: Probiotic Arm

  • Placebo comparator
    Placebo Arm

    Placebo supplement arm, 2 capsules consumed/day for a period of 28 days.

    Dietary Supplement: Placebo Arm

Interventions

  • Dietary supplementProbioticStudies of ProbioticProbiotic pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    1 x10\^9 cfu Streptococcus thermophilus (FX856), corn starch, anti-caking agent in a hydroxypropylmethycellulose \& pectin capsule.

  • Dietary supplementPlacebo Arm

    corn starch, anti-caking agent in a hydroxypropylmethycellulose \& pectin capsule.

07

What researchers measure

Primary outcomes

  1. Assess effects of FX856 on faecal calprotectin

    The level of calprotectin in faecal samples will be measured by immunoassay in all participants to determine if FX856 consumption can decrease it.

    Time frame: Change over 28 days comparison between treatments

Secondary outcomes

  1. Assess effect of FX856 treatment on gastrointestinal symptoms

    Measured by questionnaire rated on scale from 0 (Dose not bother me at all) to 10 (Is as bad as I can imagine)

    Time frame: Change over 28 days comparison between treatments

  2. Assess effect of FX856 on circulating inflammatory cytokines IFN-γ

    Measured by ELISA

    Time frame: Change over 28 days comparison between treatments

  3. Assess effect of FX856 on circulating inflammatory cytokines IL-1β

    Measured by ELISA

    Time frame: Change over 28 days comparison between treatments

  4. Assess effect of FX856 on circulating inflammatory cytokines IL-6

    Measured by ELISA

    Time frame: Change over 28 days comparison between treatments

  5. Assess effect of FX856 on circulating inflammatory cytokines TNF-α

    Measured by ELISA

    Time frame: Change over 28 days comparison between treatments

  6. Assess effect of FX856 on Cholesterol

    Measured by ILab 650 chemistry analyser using CHOD-PAP/GPO-PAP colorimetric end-point assays.

    Time frame: Change over 28 days comparison between treatments

  7. Assess effect of FX856 on LDL cholesterol

    Measured by ILab 650 chemistry analyser using CHOD-PAP/GPO-PAP colorimetric end-point assays. LDL concentrations calculated using the Friedewald formula.

    Time frame: Change over 28 days comparison between treatments

  8. Assess effect of FX856 on HDL cholesterol

    Measured via ILab 650 chemistry analyser using CHOD-PAP/GPO-PAP colorimetric end-point assays.

    Time frame: Change over 28 days comparison between treatments

  9. Assess effects of FX856 on microbiota

    The composition of gut microbiota from faecal samples will be measured by NGS pre and post consumption in all participants to determine if FX856 consumption alters the gut microbiota.

    Time frame: Change over 28 days comparison between treatments

  10. Assess effects of FX856 on faecal metabolome

    The faecal metabolome from faecal samples will be measured by untargeted mass spec pre and post consumption in all participants to determine if FX856 consumption alters the faecal metabolome.

    Time frame: Change over 28 days comparison between treatments

  11. Assess effects of FX856 on blood metabolome

    The blood metabolome will be measured by untargeted mass spec pre and post consumption in all participants to determine if FX856 consumption alters the blood metabolome.

    Time frame: Change over 28 days comparison between treatments

08

Study locations

1 site
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Sep 2028, 34 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 34 months is above that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2025
First posted
Nov 28, 2025
StartActual
Oct 14, 2025
Primary completionEst.
Sep 1, 2028
CompletionEst.
Sep 1, 2028
Last update
Nov 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07253155
Lead sponsor
University of Ulster
Collaborators
Ferryx Limited
Responsible party
Sponsor
First posted
Nov 28, 2025
Start date
Oct 14, 2025
Primary completion
Sep 1, 2028 (estimated)
Completion
Sep 1, 2028 (estimated)
Last update
Nov 28, 2025

Study contacts

Chris Gill, PhD
principal investigator · Ulster University, Human Intervention Studies Unit, Coleraine, Co. Londonderry, BT52 1SA, United Kingdom.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Probiotic

Start the discussion